Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Acquired by Virtu Financial LLC

Virtu Financial LLC boosted its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) by 318.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,356 shares of the company’s stock after purchasing an additional 35,286 shares during the period. Virtu Financial LLC owned about 0.08% of Design Therapeutics worth $249,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in shares of Design Therapeutics by 2.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,110 shares of the company’s stock valued at $396,000 after buying an additional 2,868 shares during the last quarter. Palumbo Wealth Management LLC raised its holdings in Design Therapeutics by 11.3% in the third quarter. Palumbo Wealth Management LLC now owns 36,774 shares of the company’s stock valued at $198,000 after acquiring an additional 3,720 shares in the last quarter. PDT Partners LLC boosted its stake in Design Therapeutics by 33.1% during the 3rd quarter. PDT Partners LLC now owns 36,099 shares of the company’s stock valued at $194,000 after acquiring an additional 8,972 shares during the last quarter. Walleye Capital LLC grew its holdings in Design Therapeutics by 16.3% during the 3rd quarter. Walleye Capital LLC now owns 70,000 shares of the company’s stock worth $377,000 after acquiring an additional 9,788 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in shares of Design Therapeutics by 75.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company’s stock worth $79,000 after purchasing an additional 10,113 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Stock Performance

Shares of Design Therapeutics stock opened at $6.25 on Wednesday. Design Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $7.77. The firm’s 50-day simple moving average is $5.83 and its 200-day simple moving average is $4.95. The firm has a market cap of $353.88 million, a PE ratio of -7.35 and a beta of 1.86.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.